[HTML][HTML] Pre-eclampsia

…, J Hyett, F da Silva Costa, K Nicolaides… - Nature reviews Disease …, 2023 - nature.com
Pre-eclampsia is a life-threatening disease of pregnancy unique to humans and a leading
cause of maternal and neonatal morbidity and mortality. Women who survive pre-eclampsia …

Preeclampsia

LA Magee, KH Nicolaides… - New England Journal of …, 2022 - Mass Medical Soc
Preeclampsia Preeclampsia complicates 2 to 4% of all pregnancies and accounts for about
46,000 maternal deaths and 500,000 fetal or newborn deaths each year. Antihypertensive …

Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic …

R Romero, K Nicolaides, A Conde-Agudelo… - American journal of …, 2012 - Elsevier
OBJECTIVE: To determine whether the use of vaginal progesterone in asymptomatic women
with a sonographic short cervix (≤ 25 mm) in the midtrimester reduces the risk of preterm …

[HTML][HTML] Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia

DL Rolnik, D Wright, LC Poon… - … England Journal of …, 2017 - Mass Medical Soc
Background Preterm preeclampsia is an important cause of maternal and perinatal death
and complications. It is uncertain whether the intake of low-dose aspirin during pregnancy …

UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation

RJM Snijders, P Noble, N Sebire, A Souka… - The Lancet, 1998 - thelancet.com
Background Prenatal diagnosis of trisomy 21 currently relies on assessment of risk followed
by invasive testing in the 5% of pregnancies at the highest estimated risk. Selection of the …

Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.

KH Nicolaides, G Azar, D Byrne, C Mansur… - British medical …, 1992 - bmj.com
OBJECTIVE--To examine the significance of fetal nuchal translucency at 10-14 weeks'
gestation in the prediction of abnormal fetal karyotype. DESIGN--Prospective screening …

Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study

RWK Chiu, R Akolekar, YWL Zheng, TY Leung, H Sun… - Bmj, 2011 - bmj.com
Objectives To validate the clinical efficacy and practical feasibility of massively parallel
maternal plasma DNA sequencing to screen for fetal trisomy 21 among high risk …

Progesterone and the risk of preterm birth among women with a short cervix

EB Fonseca, E Celik, M Parra, M Singh… - Obstetrical & …, 2007 - journals.lww.com
Although progesterone given prophylactically to women with a history of preterm birth cuts
the recurrence rate in half, only about 10% of spontaneous early preterm births take place in …

A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated …

K Spencer, V Souter, N Tul, R Snijders… - … in Obstetrics and …, 1999 - Wiley Online Library
Objective To examine the potential impact of combining maternal age with fetal nuchal
translucency thickness and maternal serum free β‐human chorionic gonadotropin (β‐hCG) …

[HTML][HTML] The International Federation of Gynecology and Obstetrics (FIGO) initiative on preeclampsia (PE): a pragmatic guide for first trimester screening and …

LC Poon, A Shennan, JA Hyett, A Kapur… - … of gynaecology and …, 2019 - ncbi.nlm.nih.gov
Preeclampsia (PE) is a multisystem disorder that typically affects 2%− 5% of pregnant
women and is one of the leading causes of maternal and perinatal morbidity and mortality …